Pharma bets a little-known form of cholesterol will underpin its next blockbuster heart drugs
Pharma thinks it’s found the next frontier in preventing heart attacks. Novartis, Amgen and Eli Lilly are among the drugmakers betting that slashing levels of a particularly bad form of cholesterol could deliver the next blockbusters in cardiology. All three of the pharmaceutical giants are in late-stage trials to test …
